Eurofins-Cerep SA
PAR:ALECR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.5), the stock would be worth €23 586.11 (48% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1 | €15 900 |
0%
|
| 3-Year Average | 1.5 | €23 586.11 |
+48%
|
| 5-Year Average | 3.1 | €50 004.09 |
+214%
|
| Industry Average | 3.1 | €49 691.4 |
+213%
|
| Country Average | 0.9 | €13 923.71 |
-12%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Eurofins-Cerep SA
PAR:ALECR
|
79.5m EUR | 1 | 11.1 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 84.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.4B USD | 1.9 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
124B USD | 1.8 | 33.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 5.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 2 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.4B USD | 3.2 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.1B USD | 7 | 46.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.8B USD | 1.6 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.8B USD | 8.2 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 0.9 |
| 70th Percentile | 1.3 |
| Max | 680.8 |
Other Multiples
Eurofins-Cerep SA
Glance View
Eurofins-Cerep SA engages in providing preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 211 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. In December 2013, it sold Cerep Inc, its American subsidiary, to Eurofins-Panlabs Inc, part of the Eurofins Scientific SE group.
